Should I buy or sell Syndax Pharmaceuticals stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SNDX shares. View SNDX analyst ratings or view top-rated stocks .

What is Syndax Pharmaceuticals' stock price target for 2024?

10 Wall Street research analysts have issued 1-year target prices for Syndax Pharmaceuticals' stock. Their SNDX share price targets range from $23.00 to $45.00. On average, they expect the company's stock price to reach $34.42 in the next year. This suggests a possible upside of 66.3% from the stock's current price. View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts .

How have SNDX shares performed in 2024?

Syndax Pharmaceuticals' stock was trading at $21.61 on January 1st, 2024. Since then, SNDX stock has decreased by 4.3% and is now trading at $20.69. View the best growth stocks for 2024 here .

When is Syndax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our SNDX earnings forecast .

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) posted its quarterly earnings data on Tuesday, February, 27th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by $0.01. During the same quarter in the prior year, the firm posted ($0.62) EPS.

What ETFs hold Syndax Pharmaceuticals' stock?

ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Loncar China Biopharma ETF (CHNA) , ALPS Medical Breakthroughs ETF (SBIO) , Range Cancer Therapeutics ETF (CNCR) , Simplify Propel Opportunities ETF (SURI) , SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC) . Simplify Health Care ETF (PINK) .

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK) , Exelixis (EXEL) , Verastem (VSTM) , Inovio Pharmaceuticals (INO) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Idera Pharmaceuticals (IDRA) , TherapeuticsMD (TXMD) and Micron Technology (MU) .

When did Syndax Pharmaceuticals IPO?

Syndax Pharmaceuticals (SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Diversified Trust Co (0.02%) and Mesirow Financial Investment Management Inc. (0.01%). Insiders that own company stock include Alexander Nolte , Briggs Morrison , Dennis Podlesak , Fabrice Egros , Keith A Goldan, Keith Katkin, Michael A Metzger , Michael L Meyers , Peter Ordentlich , Pierre Legault and William Meury. View institutional ownership trends .

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:SNDX

Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free SNDX Stock Alerts

$20.80

+0.31 (+1.51%)

(As of 05:37 PM ET)

Compare

Today's Range: $20.36
▼
$21.12
50-Day Range: $20.49
▼
$24.57
52-Week Range: $11.22
▼
$25.34

Volume: 942,561 shs
Average Volume: 1.16 million shs
Market Capitalization: $1.77 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.42

Get Syndax Pharmaceuticals alerts:

Syndax Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 66.3% Upside
$34.42 Price Target
Short Interest: Bearish
11.32% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.12
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.70) to ($2.86) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.88 out of 5 stars

Medical Sector

379th out of 918 stocks

Pharmaceutical Preparations Industry

166th out of 417 stocks

3.5

Analyst's Opinion

Consensus Rating
Syndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Syndax Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.32% of the outstanding shares of Syndax Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 8.2.
Change versus previous month
Short interest in Syndax Pharmaceuticals has recently increased by 15.49%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Syndax Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Syndax Pharmaceuticals does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Syndax Pharmaceuticals has received a 66.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Syndax Pharmaceuticals is -1.12.

0.8

News and Social Media Coverage

News Sentiment
Syndax Pharmaceuticals has a news sentiment score of -0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Syndax Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Syndax Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.10% of the stock of Syndax Pharmaceuticals is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($3.70) to ($2.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Syndax Pharmaceuticals is -6.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Syndax Pharmaceuticals is -6.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Syndax Pharmaceuticals has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

SNDX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SNDX Stock News Headlines

April 18, 2024 | americanbankingnews.com

Financial Analysis: Syndax Pharmaceuticals (NASDAQ:SNDX) and Biofrontera (NASDAQ:BFRI)

April 10, 2024 | finance.yahoo.com

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 10, 2024 | prnewswire.com

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

April 8, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)

April 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth Prospects

April 8, 2024 | prnewswire.com

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

April 6, 2024 | finanznachrichten.de

Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 3, 2024 | msn.com

Crinetics Pharmaceuticals gains amid pitch at Sohn charity conference (update)

March 29, 2024 | msn.com

20 European Cities with Highest Weed Consumption

March 29, 2024 | msn.com

This longevity company is letting you check the ‘credit score’ for your health. Here are my surprising results and biological age

March 28, 2024 | msn.com

Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA

March 28, 2024 | finance.yahoo.com

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

March 28, 2024 | seekingalpha.com

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

March 27, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Quanterix (QTRX)

March 27, 2024 | marketwatch.com

Syndax Says Revumenib NDA Granted FDA Priority Review

March 27, 2024 | markets.businessinsider.com

Syndax Announces FDA Priority Review Of NDA For Revumenib For Treatment Of R/R KMT2Ar Acute Leukemia

March 27, 2024 | msn.com

FDA grants priority review for Syndax leukemia drug, sets action date

March 27, 2024 | finance.yahoo.com

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

March 18, 2024 | finanznachrichten.de

Syndax Pharmaceuticals: Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

March 18, 2024 | finance.yahoo.com

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

March 16, 2024 | finance.yahoo.com

SNDX Apr 2024 17.500 put

March 13, 2024 | finance.yahoo.com

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

March 6, 2024 | markets.businessinsider.com

Buy Rating for Syndax Pharmaceuticals Amidst Strategic Progress and Regulatory Milestones

March 3, 2024 | finance.yahoo.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2023 Earnings Call Transcript

March 1, 2024 | prnewswire.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

See More Headlines

Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SNDX
CUSIP: N/A
CIK: 1395937
Web: www.syndax.com
Phone: (781) 419-1400
Fax: 781-419-1420
Employees: 184
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $34.42
High Stock Price Target: $45.00
Low Stock Price Target: $23.00
Potential Upside/Downside: +65.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-209,360,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -47.88%
Return on Assets: -44.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.00
Quick Ratio: 10.00

Sales & Book Value

Annual Sales: $139.71 million
Price / Sales: 12.65
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.53 per share
Price / Book: 3.19

Miscellaneous

Outstanding Shares: 84,960,000
Free Float: 81,481,000
Market Cap: $1.77 billion
Optionable: Optionable
Beta: 1.03

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Michael A. Metzger M.B.A. (Age 53)
CEO & Director
Comp: $1.1M
Dr. Peter Ordentlich B.Sc. (Age 55)
Ph.D., Co-Founder & Chief Scientific Officer
Dr. Richard A. Heyman Ph.D. (Age 67)
Co-Founder
Dr. Ronald M. Evans Ph.D. (Age 75)
Co-Founder, Advisor and Chair of Scientific Advisory Board
Dr. Michael Downes Ph.D.
Co-Founder
Sharon Klahre
Vice President of Investor Relations & Communications
Mr. Kevin McManus (Age 55)
Chief People Officer
Dr. Joseph Paul Eder M.D.
Member of Scientific Advisory Board & Chief Medical Officer
Dr. Anjali Ganguli Ph.D. (Age 47)
Chief Business Officer
Comp: $450.58k
Mr. Steven Closter
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SNDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Syndax Pharmaceuticals stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SNDX shares.
View SNDX analyst ratings or view top-rated stocks.
What is Syndax Pharmaceuticals' stock price target for 2024?: 10 Wall Street research analysts have issued 1-year target prices for Syndax Pharmaceuticals' stock. Their SNDX share price targets range from $23.00 to $45.00. On average, they expect the company's stock price to reach $34.42 in the next year. This suggests a possible upside of 66.3% from the stock's current price.
View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts.
How have SNDX shares performed in 2024?: Syndax Pharmaceuticals' stock was trading at $21.61 on January 1st, 2024. Since then, SNDX stock has decreased by 4.3% and is now trading at $20.69.
View the best growth stocks for 2024 here.
When is Syndax Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our SNDX earnings forecast.
How were Syndax Pharmaceuticals' earnings last quarter?: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) posted its quarterly earnings data on Tuesday, February, 27th. The company reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by $0.01. During the same quarter in the prior year, the firm posted ($0.62) EPS.
What ETFs hold Syndax Pharmaceuticals' stock?: ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include Loncar China Biopharma ETF (CHNA), ALPS Medical Breakthroughs ETF (SBIO), Range Cancer Therapeutics ETF (CNCR), Simplify Propel Opportunities ETF (SURI), SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Simplify Health Care ETF (PINK).

What other stocks do shareholders of Syndax Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).
When did Syndax Pharmaceuticals IPO?: Syndax Pharmaceuticals (SNDX) raised $66 million in an IPO on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.
Who are Syndax Pharmaceuticals' major shareholders?: Syndax Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Diversified Trust Co (0.02%) and Mesirow Financial Investment Management Inc. (0.01%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith A Goldan, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich, Pierre Legault and William Meury.
View institutional ownership trends.
How do I buy shares of Syndax Pharmaceuticals?: Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNDX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial